Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million

share with twitter share with LinkedIn share with facebook
share via e-mail
12/26/2019 | 11:43pm EDT
Astellas Pharma's logo is pictured at its headquarters in Tokyo

Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition announced this month.

Japan's second biggest drugmaker by sales paid $120 million upfront for Xyphos and the rest will be milestone payments, the companies said in a statement.

Astellas also said this month it had agreed to purchase Audentes Therapeutics Inc for about $3 billion to expand its push into genetic medicines. The deal is due to close in January.

Immuno-oncology, which seeks to use the body's own defense systems to fight cancer, is a primary focus for Astellas and under the deal, the Japanese firm will gain Xyphos' cell therapy technology platform and its research team.

"Combining this technology with our capabilities in cell therapy that we have been working on so far, we can create next-generation high-function cells and maximize the value of our technology," Astellas President Kenji Yasukawa said in the statement.

Xyphos' proprietary molecules can be delivered to natural immune cells or to engineered Chimeric Antigen Receptor (CAR) cells to generate immunotherapies for oncology.

Xyphos' first CAR cell product candidate is in preclinical development and is scheduled to be tested in a first-in-human clinical study in 2021, the statement said.

Both Xyphos and Audentes are based in San Francisco, a hub for biotech companies that are fetching huge premiums for global pharma companies eager to bolster their drug pipelines.

Japanese companies have agreed to more than 30 overseas acquisitions worth about $6 billion in the healthcare sector this year, according to Refinitiv data. That's still dwarfed by the $59 billion takeover of Britain's Shire Plc by Japanese market leader Takeda Pharmaceutical Co Ltd announced in 2018.

Astellas' purchase of Audentes was its second biggest on record after its 2010 purchase of OSI Pharmaceuticals Inc for $3.8 billion.

In the wake of the Audentes deal, Moody's put its A1 ratings on Astellas under review for a downgrade, saying the company's willingness to use debt to fund the purchase, worth 8 times the target's book equity, signaled an "an urgency for Astellas to feed its long-term product pipeline."

Shares in Astellas gained 0.7%, outperforming a largely flat broader market <.N225> ahead of the New Year holiday.

By Rocky Swift

Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. 2.56% 1699.5 End-of-day quote.2.32%
AUDENTES THERAPEUTICS, INC. 0.00%End-of-day quote.0.22%
TAKEDA PHARMACEUTICAL COMPANY LIMITED 0.46% 3487 End-of-day quote.-0.23%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on TAKEDA PHARMACEUTICAL COMP
04/07TAKEDA PHARMACEUTICAL : European Commission Approves Takeda's ALUNBRIG as a Firs..
AQ
04/07CSL Behring - Global Plasma Leaders Collaborate to Accelerate Development of ..
AQ
04/07The CSL Group collaborates with Global Plasma Leaders to accelerate developme..
AQ
04/06TAKEDA PHARMACEUTICAL : European Commission Approves Takeda's ALUNBRIG® (brigati..
BU
04/06TAKEDA PHARMACEUTICAL : CORRECTING and REPLACING Global Plasma Leaders Collabora..
BU
04/03NIKKEI : Japan's banks and borrowers battle over lending benchmark as clock tick..
RE
04/01NUVO PHARMACEUTICALS : Announces Approval of Takeda's Cabpirin Tablets in Japan,..
AQ
04/01TAKEDA PHARMACEUTICAL : Receives Positive CHMP Opinion for ADCETRIS in Combinati..
AQ
04/01TAKEDA PHARMACEUTICAL : Announces Advancement of the Operation for the Shonan He..
PU
03/31TAKEDA PHARMACEUTICAL : Adopts Executive Compensation Recoupment Policy
PU
More news
Financials (JPY)
Sales 2020 3 318 B
EBIT 2020 37 690 M
Net income 2020 -149 736 M
Debt 2020 3 996 B
Yield 2020 5,16%
P/E ratio 2020 -36,3x
P/E ratio 2021 33,1x
EV / Sales2020 2,84x
EV / Sales2021 2,74x
Capitalization 5 432 B
Chart TAKEDA PHARMACEUTICAL COMP
Duration : Period :
Takeda Pharmaceutical Comp Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMP
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Average target price 5 533,57  JPY
Last Close Price 3 487,00  JPY
Spread / Highest target 109%
Spread / Average Target 58,7%
Spread / Lowest Target 17,6%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Yasuhiko Yamanaka Director
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-0.23%49 635
JOHNSON & JOHNSON-4.19%362 446
ROCHE HOLDING AG0.67%277 253
MERCK & CO., INC-13.62%198 371
NOVARTIS-9.90%193 214
PFIZER, INC.-14.22%186 456